Selective beta-1 adrenergic receptor blocker used to lower blood pressure. No significant membrane stabilizing or intrinsic sympathomimetic effects. In high doses, it can inhibit beta-2 adrenergic receptors. It is 4 times more selective for beta-1 receptors than atenolol.

It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

It has the effect of constricting the capillaries in the upper respiratory tract, eliminating congestion in the nasopharyngeal mucosa and alleviating symptoms of nasal congestion.

It is an antihistamine with strong antihistamine and sedative effects, which can further alleviate symptoms such as nasal congestion and runny nose caused by colds.

A selective beta-1 adrenergic receptor blocker, clinically used to lower blood pressure. Within the therapeutic dose range, it has no significant membrane stabilizing effect or intrinsic sympathomimetic effect. At high doses, it can inhibit beta-2 adrenergic receptors. Its selectivity for beta-1 receptors is 4 times that of atenolol.

It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs.

It is an antihistamine that can relieve runny nose, nasal congestion, and sneezing symptoms.

It has antipyretic and sedative effects

Liranabate is a thiocarbamate antifungal drug and a squalene epoxidase inhibitor. It exerts its antifungal effect by inhibiting the epoxidation reaction of squalene in fungal cell membranes and affecting the synthesis of ergosterol, a component of cell membranes. Liranabate has a strong antifungal effect on skin filamentous fungi (Trichophyton, Microsporum, Epidermophyton), and also shows antifungal effects on other filamentous fungi, dark fungi, and dimorphic fungi.